Table 1.
Characteristics of the patients included in the REVE-2 study (n = 246).
| Characteristics | All | men | Women |
|---|---|---|---|
| n | 246 | 200 | 46 |
| Age, yr (mean ± SD) | 57 ± 14 | 56 ± 13 | 62 ± 15 |
| Diabetes mellitus | 51 (21%) | 46 (23%) | 5 (11%) |
| Initial reperfusion therapy | |||
| Primary percutaneous coronary intervention | 128 (52%) | 106 (43%) | 22 (48%) |
| Thombolysis alone | 28 (11%) | 23 (9%) | 5 (11%) |
| Thombolysis and rescue percutaneous intervention | 59 (24%) | 50 (20%) | 9 (20%) |
| No reperfusion | 31 (13%) | 21 (11%) | 10 (22%) |
| Peak creatitine kinase, IU (mean ± SD) | 3018 ± 2376 | 3099 ± 2483 | 2666 ± 1824 |
| HF (Killip class ≥2) during hospitalization | 79 (32%) | 65 (33%) | 14 (30%) |
| LVEF, % (mean ± SD) | 49 ± 8 | 49 ± 8 | 51 ± 9 |
| Medications at discharge | |||
| Antiplatelet therapy | 246 (100%) | 200 (100%) | 46 (100%) |
| β-blokers | 238 (97%) | 194 (97%) | 44 (96%) |
| ACE inhibitors | 238 (97%) | 193 (97%) | 45 (98%) |
| Statins | 231 (94%) | 189 (95%) | 42 (91%) |
| One-year echocardiography follow-up | |||
| Number of patients with follow-up | 223 (92%) | 182 (91%) | 44 (96%) |
| LV remodeling*, n | 87 (38.5%#) | 67 (36.8%#) | 20 (45.5%#) |
ACE indicates angiotensin-converting enzyme; HF, heart failure; IU, International units; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; and LVEF, left ventricular ejection fraction.*Defined as a >20% change in LVEDV between baseline and 12 months. #Of the patients with echocardiographic follow-up.